Media headlines about Sierra Oncology (NASDAQ:SRRA) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Sierra Oncology earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.4133179308207 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Several equities analysts have recently commented on the company. ValuEngine upgraded Sierra Oncology from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Zacks Investment Research upgraded Sierra Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday, November 14th. Finally, Jefferies Group upgraded Sierra Oncology from a “hold” rating to a “buy” rating in a research report on Monday, October 23rd. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. Sierra Oncology has a consensus rating of “Hold” and a consensus price target of $4.00.
Sierra Oncology (NASDAQ:SRRA) opened at $3.23 on Monday. The company has a market capitalization of $175.44 and a P/E ratio of -3.40. Sierra Oncology has a 52 week low of $1.10 and a 52 week high of $3.59.
TRADEMARK VIOLATION NOTICE: This story was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.com-unik.info/2017/12/25/sierra-oncology-srra-receiving-somewhat-favorable-news-coverage-analysis-shows.html.
Sierra Oncology Company Profile
Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.
Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.